Venture Connection entrepreneur applications are now open. Taking place during the Invent Penn State Venture & IP Conference, April 28-29, Venture Connection is a matchmaking event between capital-seeking startups and venture capital investors who have been pre-matched based on industry and capital needs, among other key criteria.
Normal pressure hydrocephalus (NPH) is a disease resulting from too much cerebrospinal fluid around the brain and affects roughly 750,000 Americans, typically those over 65 years old. Penn State researchers are developing a new technology called HydroFix, an advanced surgical shunt system to address NPH.
Penn State startup aims to improve treatment of hydrocephalus
Normal pressure hydrocephalus is a disease resulting from too much cerebrospinal fluid around the brain. NPH symptoms are often confused with Alzheimer’s disease but in many cases are reversible with the placement of a shunt. The HydroFix shunt developed by Penn State researchers is designed to mitigate the risks associated with the current shunts on the market and provide a durable treatment solution for NPH patients.Image: Penn State
Penn State startup aims to improve treatment of hydrocephalus
May 28, 2021
UNIVERSITY PARK, Pa. Normal pressure hydrocephalus (NPH) is a disease resulting from too much cerebrospinal fluid (CSF) around the brain and affects roughly 750,000 Americans, typically those over 65 years old. Symptoms are often confused with Alzheimer’s disease, but in many cases they are reversible with the placement of a shunt.